These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 8315480

  • 1. Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I study.
    Kramer EL, DeNardo SJ, Liebes L, Kroger LA, Noz ME, Mizrachi H, Salako QA, Furmanski P, Glenn SD, DeNardo GL.
    J Nucl Med; 1993 Jul; 34(7):1067-74. PubMed ID: 8315480
    [Abstract] [Full Text] [Related]

  • 2. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.
    DeNardo SJ, Kramer EL, O'Donnell RT, Richman CM, Salako QA, Shen S, Noz M, Glenn SD, Ceriani RL, DeNardo GL.
    J Nucl Med; 1997 Aug; 38(8):1180-5. PubMed ID: 9255145
    [Abstract] [Full Text] [Related]

  • 3. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
    Carrasquillo JA, White JD, Paik CH, Raubitschek A, Le N, Rotman M, Brechbiel MW, Gansow OA, Top LE, Perentesis P, Reynolds JC, Nelson DL, Waldmann TA.
    J Nucl Med; 1999 Feb; 40(2):268-76. PubMed ID: 10025834
    [Abstract] [Full Text] [Related]

  • 4. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
    Wong JY, Thomas GE, Yamauchi D, Williams LE, Odom-Maryon TL, Liu A, Esteban JM, Neumaier M, Dresse S, Wu AM, Primus FJ, Shively JE, Raubitschek AA.
    J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
    [Abstract] [Full Text] [Related]

  • 5. Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer.
    Kramer EL, Liebes L, Wasserheit C, Noz ME, Blank EW, Zabalegui A, Melamed J, Furmanski P, Peterson JA, Ceriani RL.
    Clin Cancer Res; 1998 Jul; 4(7):1679-88. PubMed ID: 9676842
    [Abstract] [Full Text] [Related]

  • 6. High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial.
    Schrier DM, Stemmer SM, Johnson T, Kasliwal R, Lear J, Matthes S, Taffs S, Dufton C, Glenn SD, Butchko G.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5921s-5924s. PubMed ID: 7493371
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of metabolism on retention of indium-111-labeled monoclonal antibody in liver and blood.
    Kinuya S, Jeong JM, Garmestani K, Saga T, Camera L, Brechbiel MW, Gansow OA, Carrasquillo JA, Neumann RD, Paik CH.
    J Nucl Med; 1994 Nov 01; 35(11):1851-7. PubMed ID: 7965168
    [Abstract] [Full Text] [Related]

  • 9. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
    Chen P, Cameron R, Wang J, Vallis KA, Reilly RM.
    J Nucl Med; 2003 Sep 01; 44(9):1469-78. PubMed ID: 12960194
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody.
    Kobayashi H, Wu C, Kim MK, Paik CH, Carrasquillo JA, Brechbiel MW.
    Bioconjug Chem; 1999 Sep 01; 10(1):103-11. PubMed ID: 9893971
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans.
    Odom-Maryon TL, Williams LE, Chai A, Lopatin G, Liu A, Wong YC, Chou J, Clarke KG, Raubitschek AA.
    J Nucl Med; 1997 Dec 01; 38(12):1959-66. PubMed ID: 9430477
    [Abstract] [Full Text] [Related]

  • 13. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
    Goodwin DA, Meares CF, Osen M.
    J Nucl Med; 1998 Oct 01; 39(10):1813-8. PubMed ID: 9776294
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    DeNardo GL, O'Donnell RT, Shen S, Kroger LA, Yuan A, Meares CF, Kukis DL, DeNardo SJ.
    J Nucl Med; 2000 May 01; 41(5):952-8. PubMed ID: 10809213
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical parameters related to optimal tumor localization of indium-111-labeled mouse antimelanoma monoclonal antibody ZME-018.
    Murray JL, Rosenblum MG, Lamki L, Glenn HJ, Krizan Z, Hersh EM, Plager CE, Bartholomew RM, Unger MW, Carlo DJ.
    J Nucl Med; 1987 Jan 01; 28(1):25-33. PubMed ID: 3794809
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.